{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:42:32Z","timestamp":1792773752297,"version":"4.5.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Platinum derivatives and taxanes are first line in the pharmacotherapy of ovarian cancer. However, both classes are associated with a wide array of adverse events (AEs). This study aimed to assess and compare AEs associated with platinum derivatives and taxanes through disproportionality analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data mining of the FAERS (FDA adverse event reporting system) database was conducted via OpenVigil 2.1 from 2003Q4 to 2024Q4. In frequentist methods, AE reports with a frequency of \u22643 were excluded, and duplicates were removed from the raw data. Proportional reporting ratio (PRR), reporting odds ratio (ROR), and chi-squared (\u03c72) were used for signal detection. Data analysis was performed using R software version 4.4.1. MedDRA version 28.0 was employed to link preferred terms (PTs) to their respective system organ classes (SOCs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>After excluding irrelevant AEs, the frequency of PTs for platinum derivatives and taxanes was 322\/246. The most reported AE in both classes was dyspnea, with 172 reports for taxanes and 272 for platinum derivatives. Reports were mainly from the USA and France, mostly involving patients aged 60\u201370\u00a0years. Disproportionality analysis flagged 150 signals for platinum derivatives and 125 for taxanes, accounting for 46.58% and 50.81% of PTs, respectively. The AEs for platinum derivatives and taxanes targeted 22 and 21 SOCs, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Signals were identified for both drug classes across multiple SOCs. AE reports were higher for platinum derivatives than taxanes, with gastrointestinal and general disorders and administration site conditions most frequently reported. Overall, the findings suggest the usefulness of FAERS data mining in identifying signals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ijpp\/riag153","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:06:17Z","timestamp":1792771577000},"source":"Crossref","is-referenced-by-count":0,"title":["Taxanes versus platinum derivatives for ovarian cancer: a comparative disproportionality analysis using the FDA adverse event reporting system database"],"prefix":"10.1093","author":[{"given":"Maria","family":"Jacob","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education , Manipal-576104, Karnataka ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha","family":"Roy Edakkarote","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education , Manipal-576104, Karnataka ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriya","family":"Lingamagunta","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education , Manipal-576104, Karnataka ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shwetha","family":"Somakumar","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education , Manipal-576104, Karnataka ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1261-4977","authenticated-orcid":false,"given":"Rajesh","family":"V","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education , Manipal-576104, Karnataka ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"2026102312061494900_ref1","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.3390\/cancers13133136","article-title":"The effects of chemotherapeutics on the ovarian cancer microenvironment","volume":"13","author":"Eckert","year":"2021","journal-title":"Cancers."},{"key":"2026102312061494900_ref2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.7497\/j.issn.2095-3941.2015.0077","article-title":"Chemotherapy of ovarian cancer in elderly patients","volume":"12","author":"Troso-Sandoval","year":"2015","journal-title":"Cancer Biol Med"},{"key":"2026102312061494900_ref3","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonz\u00e1lez-Mart\u00edn","year":"2023","journal-title":"Ann Oncol"},{"key":"2026102312061494900_ref4","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ygyno.2003.08.017","article-title":"Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel: the Memorial Sloan-Kettering Cancer Center experience","volume":"91","author":"Dizon","year":"2003","journal-title":"Gynecol Oncol"},{"key":"2026102312061494900_ref5","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1006\/gyno.2000.5958","article-title":"Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy","volume":"79","author":"Zanotti","year":"2000","journal-title":"Gynecol Oncol"},{"key":"2026102312061494900_ref6","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000320579","article-title":"Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma","volume":"78","author":"Abaid","year":"2010","journal-title":"Oncology"},{"key":"2026102312061494900_ref7","first-page":"284","article-title":"Adverse drug reaction profiles of commonly used platinum compounds in cancer chemotherapy","volume":"4","author":"Swathi","year":"2015","journal-title":"Int J Basic Clin Pharmacol"},{"key":"2026102312061494900_ref8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.18203\/2319-2003.ijbcp20223350","article-title":"Taxanes induced hypersensitivity reactions in cancer chemotherapy patients reported at adverse drug reaction monitoring Centre at a tertiary care hospital","volume":"12","author":"Begum","year":"2023","journal-title":"Int J Basic Clin Pharmacol"},{"key":"2026102312061494900_ref9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00018-018-2954-1","article-title":"Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells","volume":"76","author":"Miku\u0142a-Pietrasik","year":"2018","journal-title":"Cell Mol Life Sci CMLS"},{"key":"2026102312061494900_ref10","doi-asserted-by":"publisher","first-page":"487","DOI":"10.7150\/ijms.8.487","article-title":"Adverse event profiles of platinum agents: data Mining of the Public Version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations","volume":"8","author":"Sakaeda","year":"2011","journal-title":"Int J Med Sci"},{"key":"2026102312061494900_ref11","doi-asserted-by":"publisher","first-page":"1012093","DOI":"10.3389\/fonc.2022.1012093","article-title":"Platinum drugs-related safety profile: the latest five-year analysis from FDA adverse event reporting system data","volume":"12","author":"Feng","year":"2023","journal-title":"Front Oncol"},{"key":"2026102312061494900_ref12"},{"key":"2026102312061494900_ref13","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.1038\/s41598-023-27687-0","article-title":"Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA adverse event reporting system database","volume":"13","author":"Li","year":"2023","journal-title":"Sci Rep"},{"key":"2026102312061494900_ref14","doi-asserted-by":"publisher","first-page":"e0157753","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA \u2013 inspection of U.S. American adverse drug events pharmacovigilance data and novel clinical applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"key":"2026102312061494900_ref15","author":"A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib - PMC [Internet]"},{"key":"2026102312061494900_ref16","doi-asserted-by":"publisher","first-page":"1758835918768232","DOI":"10.1177\/1758835918768232","article-title":"First-line treatment of ovarian cancer: questions and controversies to address","volume":"10","author":"Ledermann","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2026102312061494900_ref17","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.3390\/ijms25031845","article-title":"Paradigm shift: a comprehensive review of ovarian cancer management in an era of advancements","volume":"25","author":"Tavares","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026102312061494900_ref18","doi-asserted-by":"publisher","volume-title":"Nat Rev Clin Oncol.","DOI":"10.1038\/s41571-024-00881-3"},{"key":"2026102312061494900_ref19","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. Every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N Engl J Med"},{"key":"2026102312061494900_ref20","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1001\/jama.2013.2813","article-title":"Effect of duloxetine on pain, function, and quality ofife among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial","volume":"309","author":"Smith","year":"2013","journal-title":"JAMA J Am Med Assoc"},{"key":"2026102312061494900_ref21","doi-asserted-by":"publisher","first-page":"1951412","DOI":"10.1155\/2023\/1951412","article-title":"Efficacy and safety of paclitaxel and carboplatin for platinum-sensitive ovarian cancer: a systematic review and meta-analysis","volume":"2023","author":"Zhou","year":"2023","journal-title":"J Clin Pharm Ther"},{"key":"2026102312061494900_ref22","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1111\/jns.12335","article-title":"Platinum-induced peripheral neurotoxicity: from pathogenesis to treatment","volume":"24","author":"Staff NP","year":"2019","journal-title":"J Peripher Nerv Syst JPNS"},{"key":"2026102312061494900_ref23","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/jnci\/81.19.1464","article-title":"Randomized trial in advanced ovarian cancer comparing cisplatin and carboplatin","volume":"81","author":"Mangioni","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"2026102312061494900_ref24","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1038\/sj.bjc.6601496","article-title":"The taxanes: toxicity and quality of life considerations in advanced ovarian cancer","volume":"89","author":"Guastalla","year":"2003","journal-title":"Br J Cancer"},{"key":"2026102312061494900_ref25","doi-asserted-by":"publisher","first-page":"15137","DOI":"10.1038\/s41598-025-99669-3","article-title":"FAERS based disproportionality analysis and network pharmacology investigation of taxanes associated drug induced liver injury","volume":"15","author":"Cheng","year":"2025","journal-title":"Sci Rep"},{"key":"2026102312061494900_ref26","doi-asserted-by":"publisher","first-page":"1251961","DOI":"10.3389\/fphar.2024.1251961","article-title":"A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor","volume":"15","author":"Pan","year":"2024","journal-title":"Front Pharmacol"},{"key":"2026102312061494900_ref27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40360-023-00702-w","article-title":"A disproportionality analysis of adverse events associated to pertuzumab in the FDA adverse event reporting system (FAERS). BMC","volume":"24","author":"Peng","year":"2023","journal-title":"Pharmacol Toxicol"},{"key":"2026102312061494900_ref28","doi-asserted-by":"publisher","first-page":"1693090","DOI":"10.3389\/fphar.2025.1693090","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod","volume":"16","author":"Wu","journal-title":"Front Pharmacol"},{"key":"2026102312061494900_ref29","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1007\/s00277-025-06480-1","article-title":"A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA adverse event reporting system (FAERS) database","volume":"104","author":"Reeves","year":"2025","journal-title":"Ann Hematol"}],"container-title":["International Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijpp\/advance-article-pdf\/doi\/10.1093\/ijpp\/riag153\/72443970\/riag153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijpp\/advance-article-pdf\/doi\/10.1093\/ijpp\/riag153\/72443970\/riag153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:06:19Z","timestamp":1792771579000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijpp\/advance-article\/doi\/10.1093\/ijpp\/riag153\/8993985"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":29,"URL":"https:\/\/doi.org\/10.1093\/ijpp\/riag153","relation":{},"ISSN":["2042-7174"],"issn-type":[{"value":"2042-7174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"article-number":"riag153"}}